Clinical Trial Update: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating alisertib in combination with endocrine therapy for hormone receptor-positive, HER2-negative breast cancer that is recurrent or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING